Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and
Regulatory Aspects

Priya      Gupta; Archu      Singh; Sadat      Shafi; Tanya      Ralli; Faheem   Hyder   Pottoo; Yasmin      Sultana; Kanchan      Kohli
Abstract

Cannabis sativa is widely used as a folk medicine in many parts of the globe and has been reported to be a treasure trove of phytoconstituents, including cannabinoids, terpenoids, and flavonoids. Accumulating evidence from various pre-clinical and clinical studies revealed the therapeutic potential of these constituents in various pathological conditions, including chronic pain, inflammation, neurological disorders, and cancer. However, the psychoactive effect and addiction potential associated with Cannabis use limited its clinical application. In the past two decades, extensive research on Cannabis has led to a resurgence of interest in the clinical application of its constituents, particularly cannabinoids. This review summarizes the therapeutic effect and molecular mechanism of various phytoconstituents of Cannabis. Furthermore, recently developed nanoformulations of Cannabis constituents have also been reviewed. Since Cannabis is often associated with illicit use, regulatory aspects are of vital importance and this review therefore also documented the regulatory aspects of Cannabis use along with clinical data and commercial products of Cannabis.
Keywords: Cannabis sativa, cannabinoids, cannabinoid receptors, neurological disorders, cancer, nanoformulation.
Graphical Abstract

[1]
Bonini, S.A.; Premoli, M.; Tambaro, S.; Kumar, A.; Maccarinelli, G.; Memo, M.; Mastinu, A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol.,  2018, 227, 300-315.
 [http://dx.doi.org/10.1016/j.jep.2018.09.004] [PMID: 30205181]

[2]
Borille, B.T.; González, M.; Steffens, L.; Ortiz, R.S.; Limberger, R.P. Cannabis sativa: A systematic review of plant analysis. Drug Analytical Research,  2017, 1(1), 1-23.
 [http://dx.doi.org/10.22456/2527-2616.73676]

[3]
Russo, E.B.; Jiang, H.E.; Li, X.; Sutton, A.; Carboni, A.; del Bianco, F.; Mandolino, G.; Potter, D.J.; Zhao, Y.X.; Bera, S.; Zhang, Y.B.; Lü, E.G.; Ferguson, D.K.; Hueber, F.; Zhao, L.C.; Liu, C.J.; Wang, Y.F.; Li, C.S. Phytochemical and genetic analyses of ancient Cannabis from Central Asia. J. Exp. Bot.,  2008, 59(15), 4171-4182.
 [http://dx.doi.org/10.1093/jxb/ern260] [PMID: 19036842]

[4]
Wu, J. Cannabis, cannabinoid receptors, and endocannabinoid system: Yesterday, today, and tomorrow. Acta Pharmacol. Sin.,  2019, 40(3), 297-299.
 [http://dx.doi.org/10.1038/s41401-019-0210-3] [PMID: 30670816]

[5]
Schofs, L.; Sparo, M.D.; Sánchez Bruni, S.F. The antimicrobial effect behind Cannabis sativa. Pharmacol. Res. Perspect.,  2021, 9(2), e00761.
 [http://dx.doi.org/10.1002/prp2.761] [PMID: 33822478]

[6]
Andre, C.M.; Hausman, J.F.; Guerriero, G. Cannabis sativa: The plant of the thousand and one molecules. Front. Plant Sci.,  2016, 7, 19.
 [http://dx.doi.org/10.3389/fpls.2016.00019] [PMID: 26870049]

[7]
Hartsel, J.A.; Eades, J.; Hickory, B.; Makriyannis, A. Cannabis sativa and Hemp. In: Nutraceuticals; Elsevier: Amsterdam, Netherlands, UK, 2016, pp. 735-754.

[8]
Mechoulam, R. The pharmacohistory of Cannabis sativa. Cannabinoids as therapeutic agents; Chapman and Hall/CRC, 2019, pp. 1-20.
 [http://dx.doi.org/10.1201/9780429260667]

[9]
Touw, M. The religious and medicinal uses of Cannabis in China, India and Tibet. J. Psychoactive Drugs,  1981, 13(1), 23-34.
 [http://dx.doi.org/10.1080/02791072.1981.10471447] [PMID: 7024492]

[10]
Zuardi, A.W. History of Cannabis as a medicine: A review. Rev. Bras. Psiquiatr.,  2006, 28(2), 153-157.
 [http://dx.doi.org/10.1590/S1516-44462006000200015] [PMID: 16810401]

[11]
Crocq, M.A. History of Cannabis and the endocannabinoid system. Dialogues Clin. Neurosci.,  2020, 22(3), 223-228.
 [http://dx.doi.org/10.31887/DCNS.2020.22.3/mcrocq] [PMID: 33162765]

[12]
Bridgeman, M.B.; Abazia, D.T. Medicinal Cannabis: History, pharmacology, and implications for the acute care setting. P&T,  2017, 42(3), 180-188.
 [PMID: 28250701]

[13]
Heilig, S. The pot book: A complete guide to Cannabis, its role in medicine, politics, science, and culture. J. Psychoactive Drugs,  2011, 43(1), 76-77.
 [http://dx.doi.org/10.1080/02791072.2011.566505]

[14]
Musto, D.F. The marihuana tax act of 1937. Arch. Gen. Psychiatry,  1972, 26(2), 101-108.
 [http://dx.doi.org/10.1001/archpsyc.1972.01750200005002] [PMID: 4551255]

[15]
Iversen, L.L. The science of marijuana; Oxford University Press: United Kingdom, 2001. 

[16]
Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci.,  2009, 30(10), 515-527.
 [http://dx.doi.org/10.1016/j.tips.2009.07.006] [PMID: 19729208]

[17]
Pratt, M; Stevens, A; Thuku, M; Hutton, B; Wieland, S; Shea, B Protocol for a scoping review of systematic reviews: Benefits and harms of medical marijuana., 2018.

[18]
Zou, S.; Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci.,  2018, 19(3), 833.
 [http://dx.doi.org/10.3390/ijms19030833] [PMID: 29533978]

[19]
Pellati, F.; Borgonetti, V.; Brighenti, V.; Biagi, M.; Benvenuti, S.; Corsi, L. Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Res. Int.,  2018, 2018, 1691428.

[20]
Kicman, A. Pędzińska-Betiuk, A.; Kozłowska, H. The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases. Eur. J. Pharmacol.,  2021, 911, 174560.
 [http://dx.doi.org/10.1016/j.ejphar.2021.174560] [PMID: 34648805]

[21]
Hanuš, L.O. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med. Res. Rev.,  2009, 29(2), 213-271.
 [http://dx.doi.org/10.1002/med.20135] [PMID: 18777572]

[22]
Hosking, R.D.; Zajicek, J.P. Therapeutic potential of Cannabis in pain medicine. Br. J. Anaesth.,  2008, 101(1), 59-68.
 [http://dx.doi.org/10.1093/bja/aen119] [PMID: 18515270]

[23]
Hasan, N.; Imran, M.; Sheikh, A.; Saad, S.; Chaudhary, G.; Jain, G.K.; Kesharwani, P.; Ahmad, F.J. Cannabis as a potential compound against various malignancies, legal aspects, advancement by exploiting nanotechnology and clinical trials. J. Drug Target.,  2022, 30(7), 709-725.
 [http://dx.doi.org/10.1080/1061186X.2022.2056188] [PMID: 35321629]

[24]
Pugazhendhi, A.; Suganthy, N.; Chau, T.P.; Sharma, A.; Unpaprom, Y.; Ramaraj, R.; Karuppusamy, I.; Brindhadevi, K. Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review. Process Biochem.,  2021, 111, 9-31.
 [http://dx.doi.org/10.1016/j.procbio.2021.08.025]

[25]
Jiang, S.; Fu, Y.; Williams, J.; Wood, J.; Pandarinathan, L.; Avraham, S.; Makriyannis, A.; Avraham, S.; Avraham, H.K. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One,  2007, 2(7), e641.
 [http://dx.doi.org/10.1371/journal.pone.0000641] [PMID: 17653268]

[26]
Deng, L.; Guindon, J.; Cornett, B.L.; Makriyannis, A.; Mackie, K.; Hohmann, A.G. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biol. Psychiatry,  2015, 77(5), 475-487.
 [http://dx.doi.org/10.1016/j.biopsych.2014.04.009] [PMID: 24853387]

[27]
Devane, W.A.; Hanuš, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science,  1992, 258(5090), 1946-1949.
 [http://dx.doi.org/10.1126/science.1470919] [PMID: 1470919]

[28]
Mechoulam, R.; Fride, E.; Di Marzo, V. Endocannabinoids. Eur. J. Pharmacol.,  1998, 359(1), 1-18.
 [http://dx.doi.org/10.1016/S0014-2999(98)00649-9] [PMID: 9831287]

[29]
Pertwee, R.G. The pharmacology of cannabinoid receptors and their ligands: An overview. Int. J. Obes.,  2006, 30(S1)(Suppl. 1), S13-S18.
 [http://dx.doi.org/10.1038/sj.ijo.0803272] [PMID: 16570099]

[30]
Di Marzo, V.; Bisogno, T.; De Petrocellis, L. Endocannabinoids and related compounds: Walking back and forth between plant natural products and animal physiology. Chem. Biol.,  2007, 14(7), 741-756.
 [http://dx.doi.org/10.1016/j.chembiol.2007.05.014] [PMID: 17656311]

[31]
Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol.,  2007, 18(2), 129-140.
 [http://dx.doi.org/10.1097/MOL.0b013e32803dbdec] [PMID: 17353660]

[32]
Radwan, M.M.; Wanas, A.S.; Chandra, S.; ElSohly, M.A. Natural cannabinoids of Cannabis and methods of analysis. Cannabis sativa l-botany and biotechnology; Springer: Cham, 2017, pp. 161-182.
 [http://dx.doi.org/10.1007/978-3-319-54564-6_7]

[33]
Hill, A.J.; Williams, C.M.; Whalley, B.J.; Stephens, G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther.,  2012, 133(1), 79-97.
 [http://dx.doi.org/10.1016/j.pharmthera.2011.09.002] [PMID: 21924288]

[34]
Pertwee, R.G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol.,  2008, 153(2), 199-215.
 [http://dx.doi.org/10.1038/sj.bjp.0707442] [PMID: 17828291]

[35]
Russo, E.B. Taming THC: Potential Cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol.,  2011, 163(7), 1344-1364.
 [http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x] [PMID: 21749363]

[36]
Razdan, R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev.,  1986, 3(2), 75-149.

[37]
Hollister, L.E.; Gillespie, H.K. Delta-8- and delta-9-tetrahydrocannabinol; Comparison in man by oral and intravenous administration. Clin. Pharmacol. Ther.,  1973, 14(3), 353-357.
 [http://dx.doi.org/10.1002/cpt1973143353] [PMID: 4698563]

[38]
Abrahamov, A.; Abrahamov, A.; Mechoulam, R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci.,  1995, 56(23-24), 2097-2102.
 [http://dx.doi.org/10.1016/0024-3205(95)00194-B] [PMID: 7776837]

[39]
 ClinicalTrials.gov Search Results. 2021. Available From: https://clinicaltrials.gov/

[40]
Consroe, P.; Wolkin, A. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J. Pharmacol. Exp. Ther.,  1977, 201(1), 26-32.
 [PMID: 850145]

[41]
Cunha, J.M.; Carlini, E.A.; Pereira, A.E.; Ramos, O.L.; Pimentel, C.; Gagliardi, R.; Sanvito, W.L.; Lander, N.; Mechoulam, R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology,  1980, 21(3), 175-185.
 [http://dx.doi.org/10.1159/000137430] [PMID: 7413719]

[42]
Trembly, B.; Sherman, M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids., Kolympari, Crete. International Association for Cannabinoid Medicines, 1990.

[43]
Zuardi, A.; Guimaraes, F.; Moreira, A. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian journal of medical biological research. Rev. Bras. Pesqui. Med. Biol.,  1993, 26(2), 213-217.

[44]
Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther.,  2006, 318(3), 1375-1387.
 [http://dx.doi.org/10.1124/jpet.106.105247] [PMID: 16728591]

[45]
Appendino, G.; Gibbons, S.; Giana, A.; Pagani, A.; Grassi, G.; Stavri, M.; Smith, E.; Rahman, M.M. Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. J. Nat. Prod.,  2008, 71(8), 1427-1430.
 [http://dx.doi.org/10.1021/np8002673] [PMID: 18681481]

[46]
Mastinu, A.; Premoli, M.; Ferrari-Toninelli, G.; Tambaro, S.; Maccarinelli, G.; Memo, M.; Bonini, S.A. Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Horm. Mol. Biol. Clin. Investig.,  2018, 36(2), 20180013.
 [http://dx.doi.org/10.1515/hmbci-2018-0013] [PMID: 29601300]

[47]
Lim, K.; See, Y.M.; Lee, J. A systematic review of the effectiveness of medical Cannabis for psychiatric, movement and neurodegenerative disorders. Clin. Psychopharmacol. Neurosci.,  2017, 15(4), 301-312.
 [http://dx.doi.org/10.9758/cpn.2017.15.4.301] [PMID: 29073741]

[48]
Devinsky, O.; Cilio, M.R.; Cross, H.; Fernandez-Ruiz, J.; French, J.; Hill, C.; Katz, R.; Di Marzo, V.; Jutras-Aswad, D.; Notcutt, W.G.; Martinez-Orgado, J.; Robson, P.J.; Rohrback, B.G.; Thiele, E.; Whalley, B.; Friedman, D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia,  2014, 55(6), 791-802.
 [http://dx.doi.org/10.1111/epi.12631] [PMID: 24854329]

[49]
Nigar, S.; Pottoo, F.H.; Tabassum, N.; Verma, S.K.; Javed, M.N. Molecular insights into the role of inflammation and oxidative stress in epilepsy. J Adv. Med. Pharm. Sci.,  2016, 2016, 1-9.
 [http://dx.doi.org/10.9734/JAMPS/2016/24441]

[50]
Fusar-Poli, P.; Crippa, J.A.; Bhattacharyya, S.; Borgwardt, S.J.; Allen, P.; Martin-Santos, R.; Seal, M.; Surguladze, S.A.; O’Carrol, C.; Atakan, Z.; Zuardi, A.W.; McGuire, P.K. Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry,  2009, 66(1), 95-105.
 [http://dx.doi.org/10.1001/archgenpsychiatry.2008.519] [PMID: 19124693]

[51]
Raucci, U.; Pietrafusa, N.; Paolino, M.C.; Di Nardo, G.; Villa, M.P.; Pavone, P.; Terrin, G.; Specchio, N.; Striano, P.; Parisi, P. Cannabidiol treatment for refractory epilepsies in pediatrics. Front. Pharmacol.,  2020, 11(586110), 586110.
 [http://dx.doi.org/10.3389/fphar.2020.586110] [PMID: 33117180]

[52]
Anderson, L.L.; Low, I.K.; Banister, S.D.; McGregor, I.S.; Arnold, J.C. Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of dravet syndrome. J. Nat. Prod.,  2019, 82(11), 3047-3055.
 [http://dx.doi.org/10.1021/acs.jnatprod.9b00600] [PMID: 31686510]

[53]
Carlini, E.A.; Leite, J.R.; Tannhauser, M.; Berardi, A.C. Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J. Pharm. Pharmacol.,  2011, 25(8), 664-665.
 [http://dx.doi.org/10.1111/j.2042-7158.1973.tb10660.x] [PMID: 4148442]

[54]
Szaflarski, J.P.; Bebin, E.M.; Cutter, G.; DeWolfe, J.; Dure, L.S.; Gaston, T.E.; Kankirawatana, P.; Liu, Y.; Singh, R.; Standaert, D.G.; Thomas, A.E.; Ver Hoef, L.W. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav.,  2018, 87, 131-136.
 [http://dx.doi.org/10.1016/j.yebeh.2018.07.020] [PMID: 30100226]

[55]
Devinsky, O.; Marsh, E.; Friedman, D.; Thiele, E.; Laux, L.; Sullivan, J.; Miller, I.; Flamini, R.; Wilfong, A.; Filloux, F.; Wong, M.; Tilton, N.; Bruno, P.; Bluvstein, J.; Hedlund, J.; Kamens, R.; Maclean, J.; Nangia, S.; Singhal, N.S.; Wilson, C.A.; Patel, A.; Cilio, M.R. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol.,  2016, 15(3), 270-278.
 [http://dx.doi.org/10.1016/S1474-4422(15)00379-8] [PMID: 26724101]

[56]
Aran, A; Cassuto, H Lubotzky, A Cannabidiol based medical Cannabis in children with autism- a retrospective feasibility study. (P3.318). Neurol.,  2018, 90(15 Supplement)

[57]
Sharma, P.; Sharma, A.; Fayaz, F.; Wakode, S.; Pottoo, F.H. Biological signatures of Alzheimer’s disease. Curr. Top. Med. Chem.,  2020, 20(9), 770-781.
 [http://dx.doi.org/10.2174/1568026620666200228095553] [PMID: 32108008]

[58]
Mir, R.H.; Shah, A.J.; Mohi-Ud-Din, R.; Pottoo, F.H.; Dar, M.A.; Jachak, S.M.; Masoodi, M.H. Natural Anti-inflammatory compounds as Drug candidates in Alzheimer’s disease. Curr. Med. Chem.,  2021, 28(23), 4799-4825.
 [http://dx.doi.org/10.2174/1875533XMTA4aNzUBx] [PMID: 32744957]

[59]
Holgado, M.A.; Martín-Banderas, L.; Álvarez-Fuentes, J.; Fernández-Arévalo, M. Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases. J. Drug Deliv. Sci. Technol.,  2017, 42, 84-93.
 [http://dx.doi.org/10.1016/j.jddst.2017.04.023]

[60]
Aso, E.; Ferrer, I. CB2 cannabinoid receptor as potential target against Alzheimer’s disease. Front. Neurosci.,  2016, 10, 243.
 [http://dx.doi.org/10.3389/fnins.2016.00243] [PMID: 27303261]

[61]
Fernández-Ruiz, J. The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol.,  2019, 176(10), 1370-1383.
 [http://dx.doi.org/10.1111/bph.14382] [PMID: 29856067]

[62]
Patton, G.C.; Coffey, C.; Carlin, J.B.; Degenhardt, L.; Lynskey, M.; Hall, W. Cannabis use and mental health in young people: Cohort study. BMJ,  2002, 325(7374), 1195-1198.
 [http://dx.doi.org/10.1136/bmj.325.7374.1195] [PMID: 12446533]

[63]
Suliman, N.A.; Taib, C.N.M.; Moklas, M.A.M.; Basir, R. Delta-9-Tetrahydrocannabinol (∆9-THC) induce neurogenesis and improve cognitive performances of male sprague dawley rats. Neurotox. Res.,  2018, 33(2), 402-411.
 [http://dx.doi.org/10.1007/s12640-017-9806-x] [PMID: 28933048]

[64]
Bilkei-Gorzo, A.; Albayram, O.; Draffehn, A.; Michel, K.; Piyanova, A.; Oppenheimer, H.; Dvir-Ginzberg, M.; Rácz, I.; Ulas, T.; Imbeault, S.; Bab, I.; Schultze, J.L.; Zimmer, A. A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat. Med.,  2017, 23(6), 782-787.
 [http://dx.doi.org/10.1038/nm.4311] [PMID: 28481360]

[65]
Aso, E.; Juvés, S.; Maldonado, R.; Ferrer, I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis.,  2013, 35(4), 847-858.
 [http://dx.doi.org/10.3233/JAD-130137] [PMID: 23515018]

[66]
Walther, S.; Mahlberg, R.; Eichmann, U.; Kunz, D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl.),  2006, 185(4), 524-528.
 [http://dx.doi.org/10.1007/s00213-006-0343-1] [PMID: 16521031]

[67]
Esposito, G.; Scuderi, C.; Savani, C.; Steardo, L., Jr; De Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V.; Steardo, L. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br. J. Pharmacol.,  2007, 151(8), 1272-1279.
 [http://dx.doi.org/10.1038/sj.bjp.0707337] [PMID: 17592514]

[68]
Shelef, A.; Barak, Y.; Berger, U.; Paleacu, D.; Tadger, S.; Plopsky, I.; Baruch, Y. Safety and efficacy of medical Cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study. J. Alzheimers Dis.,  2016, 51(1), 15-19.
 [http://dx.doi.org/10.3233/JAD-150915] [PMID: 26757043]

[69]
Eggers, C.; Fujitani, M.; Kato, R.; Smid, S. Novel Cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone. Biochem. Pharmacol.,  2019, 169, 113609.
 [http://dx.doi.org/10.1016/j.bcp.2019.08.011] [PMID: 31437460]

[70]
Franke, T.; Irwin, C.; Beindorff, N.; Bouter, Y.; Bouter, C. Effects of tetrahydrocannabinol treatment on brain metabolism and neuron loss in a mouse model of sporadic Alzheimer’s disease. Nucl. Med.,  2019, 58(02), 94.

[71]
Kumar, B.; Pandey, M.; Fayaz, F.; Izneid, T.A.; Pottoo, F.H.; Manchanda, S.; Sharma, A.; Sahoo, P.K. Applications of Exosomes in targeted drug delivery for the treatment of Parkinson’s Disease: A review of recent advances and clinical challenges. Curr. Top. Med. Chem.,  2020, 20(30), 2777-2788.
 [http://dx.doi.org/10.2174/1568026620666201019112557] [PMID: 33076810]

[72]
Sharma, S.; Rabbani, S.A.; Agarwal, T.; Baboota, S.; Pottoo, F.H.; Kadian, R. Nanotechnology driven approaches for the management of Parkinson’s Dis-ease: Current status and future perspectives. Curr. Drug Metab.,  2021, 22(4), 287-298.
 [http://dx.doi.org/10.2174/18755453MTExhNzY00] [PMID: 33234098]

[73]
Köfalvi, A. Alternative interacting sites and novel receptors for cannabinoid ligands. Cannabinoids and the brain; Springer: Cham, 2008, pp. 131-160.

[74]
García, C.; Palomo-Garo, C.; García-Arencibia, M.; Ramos, J.A.; Pertwee, R.G.; Fernández-Ruiz, J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol.,  2011, 163(7), 1495-1506.
 [http://dx.doi.org/10.1111/j.1476-5381.2011.01278.x] [PMID: 21323909]

[75]
Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernández-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson’s disease. Neurobiol. Dis.,  2005, 19(1-2), 96-107.
 [http://dx.doi.org/10.1016/j.nbd.2004.11.009] [PMID: 15837565]

[76]
Gonçalves, J.; Rosado, T.; Soares, S.; Simão, A.; Caramelo, D.; Luís, Â.; Fernández, N.; Barroso, M.; Gallardo, E.; Duarte, A. Cannabis and its secondary metabolites: Their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicines,  2019, 6(1), 31.
 [http://dx.doi.org/10.3390/medicines6010031] [PMID: 30813390]

[77]
Peres, F.F.; Levin, R.; Suiama, M.A.; Diana, M.C.; Gouvêa, D.A.; Almeida, V.; Santos, C.M.; Lungato, L.; Zuardi, A.W.; Hallak, J.E.C.; Crippa, J.A.; Vânia, D.A.; Silva, R.H.; Abílio, V.C. Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Front. Pharmacol.,  2016, 7, 343.
 [http://dx.doi.org/10.3389/fphar.2016.00343] [PMID: 27733830]

[78]
Consroe, P.; Sandyk, R.; Snider, S.R. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci.,  1986, 30(4), 277-282.
 [http://dx.doi.org/10.3109/00207458608985678] [PMID: 3793381]

[79]
Zuardi, A.W.; Crippa, J.; Hallak, J.E.C.; Pinto, J.P.; Chagas, M.H.N.; Rodrigues, G.G.R.; Dursun, S.M.; Tumas, V. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J. Psychopharmacol.,  2009, 23(8), 979-983.
 [http://dx.doi.org/10.1177/0269881108096519] [PMID: 18801821]

[80]
Kumar, S.; Singh, P.; Sharma, S.; Ali, J.; Baboota, S.; Pottoo, F.H. Proteomic analysis of Huntington’s Disease. Curr. Protein Pept. Sci.,  2020, 21(12), 1218-1222.
 [http://dx.doi.org/10.2174/1389203721666201006160327] [PMID: 33023443]

[81]
Muñoz-Rubio, I.; Cózar-Bernal, M.; Álvarez-Fuentes, J.; Martín-Banderas, L.; Fernández-Arévalo, M.; Holgado, M.J.I.F. Aplicaciones de los cannabinoides como agentes terapéuticos. Gac. Med. Mex.,  2011, 163, 68-77.

[82]
Blázquez, C.; Chiarlone, A.; Sagredo, O.; Aguado, T.; Pazos, M.R.; Resel, E.; Palazuelos, J.; Julien, B.; Salazar, M.; Börner, C.; Benito, C.; Carrasco, C.; Diez-Zaera, M.; Paoletti, P.; Díaz-Hernández, M.; Ruiz, C.; Sendtner, M.; Lucas, J.J.; de Yébenes, J.G.; Marsicano, G.; Monory, K.; Lutz, B.; Romero, J.; Alberch, J.; Ginés, S.; Kraus, J.; Fernández-Ruiz, J.; Galve-Roperh, I.; Guzmán, M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain,  2011, 134(1), 119-136.
 [http://dx.doi.org/10.1093/brain/awq278] [PMID: 20929960]

[83]
Abdel-Salam, O. Cannabis for Basal Ganglia Disorders (Parkinson Disease and Huntington Disease). In: Handbook of Cannabis and Related Pathologies; Elsevier: Amsterdam, Netherlands, 2017, pp. 917-930.

[84]
Sandyk, R.; Consroe, P.; Stern, L.; Snider, S. Effects of cannabidiol in Huntington’s disease. Neurology,  1986, 36(Suppl. 1), 342.

[85]
Consroe, P.; Laguna, J.; Allender, J.; Snider, S.; Stern, L.; Sandyk, R.; Kennedy, K.; Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav.,  1991, 40(3), 701-708.
 [http://dx.doi.org/10.1016/0091-3057(91)90386-G] [PMID: 1839644]

[86]
Curtis, A.; Mitchell, I.; Patel, S.; Ives, N.; Rickards, H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov. Disord.,  2009, 24(15), 2254-2259.
 [http://dx.doi.org/10.1002/mds.22809] [PMID: 19845035]

[87]
López-Sendón Moreno, J.L.; García Caldentey, J.; Trigo Cubillo, P.; Ruiz Romero, C.; García Ribas, G.; Alonso Arias, M.A.A.; García de Yébenes, M.J.; Tolón, R.M.; Galve-Roperh, I.; Sagredo, O.; Valdeolivas, S.; Resel, E.; Ortega-Gutierrez, S.; García-Bermejo, M.L.; Fernández Ruiz, J.; Guzmán, M.; García de Yébenes Prous, J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J. Neurol.,  2016, 263(7), 1390-1400.
 [http://dx.doi.org/10.1007/s00415-016-8145-9] [PMID: 27159993]

[88]
Chayasirisobhon, S. Cannabis and Neuropsychiatric Disorders: An Updated Review. Acta Neurol. Taiwan.,  2019, 28(2), 27-39.
 [PMID: 31867704]

[89]
Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; Schmidlkofer, S.; Westwood, M.; Kleijnen, J. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA,  2015, 313(24), 2456-2473.
 [http://dx.doi.org/10.1001/jama.2015.6358] [PMID: 26103030]

[90]
Lee, J.L.C.; Bertoglio, L.J.; Guimarães, F.S.; Stevenson, C.W. Cannabidiol regulation of emotion and emotional memory processing: Relevance for treating anxiety-related and substance abuse disorders. Br. J. Pharmacol.,  2017, 174(19), 3242-3256.
 [http://dx.doi.org/10.1111/bph.13724] [PMID: 28268256]

[91]
Campos, A.C.; Guimarães, F.S. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology,  2008, 199(2), 223-230.
 [http://dx.doi.org/10.1007/s00213-008-1168-x] [PMID: 18446323]

[92]
Bisogno, T.; Hanuš, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, D.E.; Brandi, I.; Moriello, A.S.; Davis, J.B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol.,  2001, 134(4), 845-852.
 [http://dx.doi.org/10.1038/sj.bjp.0704327] [PMID: 11606325]

[93]
Papagianni, E.P.; Stevenson, C.W. Cannabinoid regulation of fear and anxiety: An update. Curr. Psychiatry Rep.,  2019, 21(6), 38.
 [http://dx.doi.org/10.1007/s11920-019-1026-z] [PMID: 31030284]

[94]
Namdar, D.; Koltai, H. Medical Cannabis for the treatment of inflammation. Nat. Prod. Commun.,  2018, 13(3), 1-6.
 [http://dx.doi.org/10.1177/1934578X1801300304]

[95]
Atalay, S.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Antioxidative and anti-inflammatory properties of Cannabidiol. Antioxidants,  2019, 9(1), 21.
 [http://dx.doi.org/10.3390/antiox9010021] [PMID: 31881765]

[96]
Burstein, S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg. Med. Chem.,  2015, 23(7), 1377-1385.
 [http://dx.doi.org/10.1016/j.bmc.2015.01.059] [PMID: 25703248]

[97]
Jamontt, J.M.; Molleman, A.; Pertwee, R.G.; Parsons, M.E. The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br. J. Pharmacol.,  2010, 160(3), 712-723.
 [http://dx.doi.org/10.1111/j.1476-5381.2010.00791.x] [PMID: 20590574]

[98]
Costa, B.; Colleoni, M.; Conti, S.; Parolaro, D.; Franke, C.; Trovato, A.E.; Giagnoni, G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of Cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch. Pharmacol.,  2004, 369(3), 294-299.
 [http://dx.doi.org/10.1007/s00210-004-0871-3] [PMID: 14963641]

[99]
Ben-Shabat, S.; Hanuš, L.O.; Katzavian, G.; Gallily, R. New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J. Med. Chem.,  2006, 49(3), 1113-1117.
 [http://dx.doi.org/10.1021/jm050709m] [PMID: 16451075]

[100]
Petrosino, S.; Verde, R.; Vaia, M.; Allarà, M.; Iuvone, T.; Di Marzo, V. Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J. Pharmacol. Exp. Ther.,  2018, 365(3), 652-663.
 [http://dx.doi.org/10.1124/jpet.117.244368] [PMID: 29632236]

[101]
Borges, R.; Batista, J., Jr; Viana, R.; Baetas, A.; Orestes, E.; Andrade, M.; Honório, K.; da Silva, A. Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. Molecules,  2013, 18(10), 12663-12674.
 [http://dx.doi.org/10.3390/molecules181012663] [PMID: 24129275]

[102]
Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Haskó, G.; Pacher, P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther.,  2009, 328(3), 708-714.
 [http://dx.doi.org/10.1124/jpet.108.147181] [PMID: 19074681]

[103]
Fouad, A.A.; Albuali, W.H.; Al-Mulhim, A.S.; Jresat, I. Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ. Toxicol. Pharmacol.,  2013, 36(2), 347-357.
 [http://dx.doi.org/10.1016/j.etap.2013.04.018] [PMID: 23721741]

[104]
Blanchard, D.K.; Newton, C.; Klein, T.W.; Stewart, W.E., II; Friedman, H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int. J. Immunopharmacol.,  1986, 8(7), 819-824.
 [http://dx.doi.org/10.1016/0192-0561(86)90020-2] [PMID: 2430904]

[105]
Cabral, G.A.; Lockmuller, J.C.; Mishkin, E.M. Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Exp. Biol. Med.,  1986, 181(2), 305-311.
 [http://dx.doi.org/10.3181/00379727-181-42258] [PMID: 3003756]

[106]
Gaffal, E.; Cron, M.; Glodde, N.; Tüting, T. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy,  2013, 68(8), 994-1000.
 [http://dx.doi.org/10.1111/all.12183] [PMID: 23889474]

[107]
Hampson, A.J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA,  1998, 95(14), 8268-8273.
 [http://dx.doi.org/10.1073/pnas.95.14.8268] [PMID: 9653176]

[108]
Chen, J.; Errico, S.L.; Freed, W.J. Reactive oxygen species and p38 phosphorylation regulate the protective effect of Δ9-tetrahydrocannabinol in the apoptotic response to NMDA. Neurosci. Lett.,  2005, 389(2), 99-103.
 [http://dx.doi.org/10.1016/j.neulet.2005.07.028] [PMID: 16098661]

[109]
Perez, E.; Fernandez, J.R.; Fitzgerald, C.; Rouzard, K.; Tamura, M.; Savile, C. In vitro and clinical evaluation of cannabigerol (CBG) produced via yeast biosynthesis: A Cannabinoid with a broad range of anti-inflammatory and skin health-boosting properties. Molecules,  2022, 27(2), 491.
 [http://dx.doi.org/10.3390/molecules27020491] [PMID: 35056807]

[110]
Borrelli, F.; Fasolino, I.; Romano, B.; Capasso, R.; Maiello, F.; Coppola, D.; Orlando, P.; Battista, G.; Pagano, E.; Di Marzo, V.; Izzo, A.A. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol.,  2013, 85(9), 1306-1316.
 [http://dx.doi.org/10.1016/j.bcp.2013.01.017] [PMID: 23415610]

[111]
Flachenecker, P.; Henze, T.; Zettl, U.K. Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life. Acta Neurol. Scand.,  2014, 129(3), 154-162.
 [http://dx.doi.org/10.1111/ane.12202] [PMID: 24256407]

[112]
Soelberg Sorensen, P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol. Scand.,  2017, 136(3), 168-186.
 [http://dx.doi.org/10.1111/ane.12712] [PMID: 27891572]

[113]
Gilman, S.; Newman, S.W.; Manter, J.T. Manter and Gatz’s essentials of clinical neuroanatomy and neurophysiology; FA Davis Company: Philadelphia, 1996. 

[114]
Śmiarowska, M.; Białecka, M.; Machoy-Mokrzyńska, A. Cannabis and cannabinoids: Pharmacology and therapeutic potential. Neurol Neurochir Pol.,  2022, 56(1), 4-13.

[115]
Pertwee, R.G. Sites and mechanisms of action. In: Pharmacol. Toxicol. Ther. Potent; Haworth Press: New York, 2002, pp. 73-87.

[116]
Koppel, B.S.; Brust, J.C.M.; Fife, T.; Bronstein, J.; Youssof, S.; Gronseth, G.; Gloss, D. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology,  2014, 82(17), 1556-1563.
 [http://dx.doi.org/10.1212/WNL.0000000000000363] [PMID: 24778283]

[117]
Nielsen, S.; Germanos, R.; Weier, M.; Pollard, J.; Degenhardt, L.; Hall, W.; Buckley, N.; Farrell, M. The use of Cannabis and cannabinoids in treating symptoms of multiple sclerosis: A systematic review of reviews. Curr. Neurol. Neurosci. Rep.,  2018, 18(2), 8.
 [http://dx.doi.org/10.1007/s11910-018-0814-x] [PMID: 29442178]

[118]
Allan, G.M.; Finley, C.R.; Ton, J.; Perry, D.; Ramji, J.; Crawford, K.; Lindblad, A.J.; Korownyk, C.; Kolber, M.R. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Can. Fam. Physician,  2018, 64(2), e78-e94.
 [PMID: 29449262]

[119]
Baker, D.; Pryce, G.; Croxford, J.L.; Brown, P.; Pertwee, R.G.; Huffman, J.W.; Layward, L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature,  2000, 404(6773), 84-87.
 [http://dx.doi.org/10.1038/35003583] [PMID: 10716447]

[120]
Keating, G.M. Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex®): A review in multiple sclerosis-related spasticity. Drugs,  2017, 77(5), 563-574.
 [http://dx.doi.org/10.1007/s40265-017-0720-6] [PMID: 28293911]

[121]
Pavisian, B.; MacIntosh, B.J.; Szilagyi, G.; Staines, R.W.; O’Connor, P.; Feinstein, A. Effects of Cannabis on cognition in patients with MS: A psychometric and MRI study. Neurology,  2014, 82(21), 1879-1887.
 [http://dx.doi.org/10.1212/WNL.0000000000000446] [PMID: 24789863]

[122]
Rudroff, T.; Honce, J.M. Cannabis and multiple sclerosis—the way forward. Front. Neurol.,  2017, 8, 299.
 [http://dx.doi.org/10.3389/fneur.2017.00299] [PMID: 28690588]

[123]
Rice, J.; Cameron, M. Cannabinoids for treatment of MS symptoms: State of the evidence. Curr. Neurol. Neurosci. Rep.,  2018, 18(8), 50.
 [http://dx.doi.org/10.1007/s11910-018-0859-x] [PMID: 29923025]

[124]
Herzog, S.; Shanahan, M.; Grimison, P.; Tran, A.; Wong, N.; Lintzeris, N.; Simes, J.; Stockler, M.; Morton, R.L. Systematic review of the costs and benefits of prescribed Cannabis-based medicines for the management of chronic illness: Lessons from multiple sclerosis. PharmacoEconomics,  2018, 36(1), 67-78.
 [http://dx.doi.org/10.1007/s40273-017-0565-6] [PMID: 28866778]

[125]
Malfitano, A.M.; Proto, M.C.; Bifulco, M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr. Dis. Treat.,  2008, 4(5), 847-853.
 [PMID: 19183777]

[126]
Dariš, B.; Tancer Verboten, M.; Knez, Ž.; Ferk, P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosn. J. Basic Med. Sci.,  2019, 19(1), 14-23.
 [http://dx.doi.org/10.17305/bjbms.2018.3532] [PMID: 30172249]

[127]
McAllister, S.D.; Soroceanu, L.; Desprez, P.Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. J. Neuroimmune Pharmacol.,  2015, 10(2), 255-267.
 [http://dx.doi.org/10.1007/s11481-015-9608-y] [PMID: 25916739]

[128]
Velasco, G.; Sánchez, C.; Guzmán, M. Anticancer mechanisms of cannabinoids. Curr. Oncol.,  2016, 23(11), 23-32.
 [http://dx.doi.org/10.3747/co.23.3080] [PMID: 27022311]

[129]
Cridge, B.J.; Rosengren, R.J. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag. Res.,  2013, 5, 301-313.
 [PMID: 24039449]

[130]
Hart, S.; Fischer, O.M.; Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res.,  2004, 64(6), 1943-1950.
 [http://dx.doi.org/10.1158/0008-5472.CAN-03-3720] [PMID: 15026328]

[131]
Sharma, M.; Hudson, J.B.; Adomat, H.; Guns, E.; Cox, M.E. in vitro anticancer activity of plant-derived cannabidiol on prostate cancer cell lines. Pharmacol. Pharm.,  2014, 5(8), 806-820.
 [http://dx.doi.org/10.4236/pp.2014.58091]

[132]
Shrivastava, A.; Kuzontkoski, P.M.; Groopman, J.E.; Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol. Cancer Ther.,  2011, 10(7), 1161-1172.
 [http://dx.doi.org/10.1158/1535-7163.MCT-10-1100] [PMID: 21566064]

[133]
Solinas, M.; Massi, P.; Cinquina, V.; Valenti, M.; Bolognini, D.; Gariboldi, M.; Monti, E.; Rubino, T.; Parolaro, D. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One,  2013, 8(10), e76918.
 [http://dx.doi.org/10.1371/journal.pone.0076918] [PMID: 24204703]

[134]
Takeda, S.; Misawa, K.; Yamamoto, I.; Watanabe, K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in Cannabis. Drug Metab. Dispos.,  2008, 36(9), 1917-1921.
 [http://dx.doi.org/10.1124/dmd.108.020909] [PMID: 18556441]

[135]
Grimaldi, C.; Pisanti, S.; Laezza, C.; Malfitano, A.M.; Santoro, A.; Vitale, M.; Caruso, M.G.; Notarnicola, M.; Iacuzzo, I.; Portella, G.; Di Marzo, V.; Bifulco, M. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res.,  2006, 312(4), 363-373.
 [http://dx.doi.org/10.1016/j.yexcr.2005.10.024] [PMID: 16343481]

[136]
Hussein, N.A.E.M.; El-Toukhy, M.A.E.F.; Kazem, A.H.; Ali, M.E.S.; Ahmad, M.A.E.R.; Ghazy, H.M.R.; El-Din, A.M.G. Protective and therapeutic effects of Cannabis plant extract on liver cancer induced by dimethylnitrosamine in mice. Alex. J. Med.,  2014, 50(3), 241-251.
 [http://dx.doi.org/10.1016/j.ajme.2014.02.003]

[137]
Hernán Pérez de la Ossa, D.; Lorente, M.; Gil-Alegre, M.E.; Torres, S.; García-Taboada, E.; Aberturas, M.R.; Molpeceres, J.; Velasco, G.; Torres-Suárez, A.I. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One,  2013, 8(1), e54795.
 [http://dx.doi.org/10.1371/journal.pone.0054795] [PMID: 23349970]

[138]
Romano, B.; Pagano, E.; Orlando, P.; Capasso, R.; Cascio, M.G.; Pertwee, R.; Marzo, V.D.; Izzo, A.A.; Borrelli, F. Pure Δ 9 - tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ 9 -tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol. Res.,  2016, 113(Pt A), 199-208.
 [http://dx.doi.org/10.1016/j.phrs.2016.07.045] [PMID: 27498155]

[139]
Reiss, C.S. Cannabinoids and Viral Infections. Pharmaceuticals,  2010, 3(6), 1873-1886.
 [http://dx.doi.org/10.3390/ph3061873] [PMID: 20634917]

[140]
Campos, A.C.; Brant, F.; Miranda, A.S.; Machado, F.S.; Teixeira, A.L. Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience,  2015, 289, 166-180.
 [http://dx.doi.org/10.1016/j.neuroscience.2014.12.051] [PMID: 25595981]

[141]
Meza, A.; Lehmann, C. Betacaryophyllene – A phytocannabinoid as potential therapeutic modality for human sepsis? Med. Hypotheses,  2018, 110, 68-70.
 [http://dx.doi.org/10.1016/j.mehy.2017.10.025] [PMID: 29317072]

[142]
Mulpuri, Y.; Marty, V.N.; Munier, J.J.; Mackie, K.; Schmidt, B.L.; Seltzman, H.H.; Spigelman, I. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropharmacology,  2018, 139, 85-97.
 [http://dx.doi.org/10.1016/j.neuropharm.2018.07.002] [PMID: 29981335]

[143]
Vučković S.; Srebro, D.; Vujović K.S.; Vučetić Č Prostran, M. Cannabinoids and pain: New insights from old molecules. Front. Pharmacol.,  2018, 9, 1259.
 [http://dx.doi.org/10.3389/fphar.2018.01259] [PMID: 30542280]

[144]
Davis, M.P. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin. Investig. Drugs,  2014, 23(8), 1123-1140.
 [http://dx.doi.org/10.1517/13543784.2014.918603] [PMID: 24836296]

[145]
Starowicz, K.; Finn, D.P. Cannabinoids and pain: Sites and mechanisms of action. Adv. Pharmacol.,  2017, 80, 437-475.
 [http://dx.doi.org/10.1016/bs.apha.2017.05.003] [PMID: 28826543]

[146]
Sharkey, K.A.; Darmani, N.A.; Parker, L.A. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur. J. Pharmacol.,  2014, 722, 134-146.
 [http://dx.doi.org/10.1016/j.ejphar.2013.09.068] [PMID: 24184696]

[147]
Taylor, B.N.; Mueller, M.; Sauls, R.S. Cannaboinoid antiemetic therapy; StatPearls: Florida, 2018. 

[148]
Parker, L.A.; Kemp, S.W.P. Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: An animal model of anticipatory nausea and vomiting (ANV). Neuroreport,  2001, 12(4), 749-751.
 [http://dx.doi.org/10.1097/00001756-200103260-00027] [PMID: 11277577]

[149]
Badowski, M.E. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother. Pharmacol.,  2017, 80(3), 441-449.
 [http://dx.doi.org/10.1007/s00280-017-3387-5] [PMID: 28780725]

[150]
 Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial. 2020. Available From: https://www.cardiolrx.com/cardiol-therapeutics-receives-fda-approval-for-investigational-new-drug-ind-application-for-phase-ii-iii-covid-19-trial/

[151]
Coughlin, L.N.; Ilgen, M.A.; Jannausch, M.; Walton, M.A.; Bohnert, K.M. Progression of Cannabis withdrawal symptoms in people using medical Cannabis for chronic pain. Addiction,  2021, 116(8), 2067-2075.
 [http://dx.doi.org/10.1111/add.15370] [PMID: 33400332]

[152]
Russo, E.; Cannas, C.; Rivetti, M.S.; Villa, C.; Rebesco, B. Innovative clinical-organizational model to ensure appropriateness and quality in the management of medical Cannabis: An Italian Regional Case. Health care,  2021, 9(11), 1425.

[153]
Onaivi, E.S.; Singh Chauhan, B.P.; Sharma, V. Challenges of cannabinoid delivery: How can nanomedicine help? Nanomedicine,  2020, 15(21), 2023-2028.
 [http://dx.doi.org/10.2217/nnm-2020-0221] [PMID: 32589080]

[154]
Ansari, M.A.; Badrealam, K.F.; Alam, A.; Tufail, S.; Khalique, G.; Equbal, M.J.; Alzohairy, M.A.; Almatroudi, A.; Alomary, M.N.; Pottoo, F.H. Recent nano-based therapeutic intervention of bioactive sesquiterpenes: Prospects in cancer therapeutics. Curr. Pharm. Des.,  2020, 26(11), 1138-1144.
 [http://dx.doi.org/10.2174/1381612826666200116151522] [PMID: 31951164]

[155]
Esposito, E.; Ravani, L.; Drechsler, M.; Mariani, P.; Contado, C.; Ruokolainen, J.; Ratano, P.; Campolongo, P.; Trezza, V.; Nastruzzi, C.; Cortesi, R. Cannabinoid antagonist in nanostructured lipid carriers (NLCs): Design, characterization and in vivo study. Mater. Sci. Eng. C,  2015, 48, 328-336.
 [http://dx.doi.org/10.1016/j.msec.2014.12.012] [PMID: 25579930]

[156]
Esposito, E.; Drechsler, M.; Cortesi, R.; Nastruzzi, C. Encapsulation of cannabinoid drugs in nanostructured lipid carriers. Eur. J. Pharm. Biopharm.,  2016, 102, 87-91.
 [http://dx.doi.org/10.1016/j.ejpb.2016.03.005] [PMID: 26952905]

[157]
Hassanzadeh, P.; Arbabi, E.; Atyabi, F.; Dinarvand, R. Carbon nanotube-anandamide complex exhibits sustained protective effects in an in vitro model of stroke. J. Physiol. Pharmacol.,  2016, 20(1), 12-23.

[158]
He, X.; Zhu, Y.; Wang, M.; Jing, G.; Zhu, R.; Wang, S. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression. Int. J. Nanomedicine,  2016, 11, 4975-4990.
 [http://dx.doi.org/10.2147/IJN.S109088] [PMID: 27757031]

[159]
Nakano, Y.; Tajima, M.; Sugiyama, E.; Sato, V.H.; Sato, H. Development of a novel nanoemulsion formulation to improve intestinal absorption of cannabidiol. Med. Cannabis Cannabinoids,  2019, 2(1), 35-42.
 [http://dx.doi.org/10.1159/000497361] [PMID: 34676332]

[160]
Chouhan, S.; Guleria, S. Green synthesis of AgNPs using Cannabis sativa leaf extract: Characterization, antibacterial, anti-yeast and α-amylase inhibitory activity. Mater. Sci. Energy Technol.,  2020, 3, 536-544.
 [http://dx.doi.org/10.1016/j.mset.2020.05.004]

[161]
Mandal, S.; Marpu, S.B.; Hughes, R.; Omary, M.A.; Shi, S.Q. Green synthesis of silver nanoparticles using Cannabis sativa extracts and their anti-bacterial activity. Green and Sustainable Chemistry,  2021, 11(1), 28-38.
 [http://dx.doi.org/10.4236/gsc.2021.111004]

[162]
Csakvari, A.C.; Moisa, C.; Radu, D.G.; Olariu, L.M.; Lupitu, A.I.; Panda, A.O.; Pop, G.; Chambre, D.; Socoliuc, V.; Copolovici, L.; Copolovici, D.M. Green synthesis, characterization, and antibacterial properties of silver nanoparticles obtained by using diverse varieties of Cannabis sativa leaf extracts. Molecules,  2021, 26(13), 4041.
 [http://dx.doi.org/10.3390/molecules26134041] [PMID: 34279380]

[163]
Chang, Y.; Zheng, C.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A. Cytotoxicity, anti-acute leukemia, and antioxidant properties of gold nanoparticles green-synthesized using Cannabis sativa L leaf aqueous extract. Arab. J. Chem.,  2021, 14(4), 103060.
 [http://dx.doi.org/10.1016/j.arabjc.2021.103060]

[164]
Levinsohn, E.A.; Hill, K.P. Clinical uses of Cannabis and cannabinoids in the United States. J. Neurol. Sci.,  2020, 411, 116717.
 [http://dx.doi.org/10.1016/j.jns.2020.116717] [PMID: 32044684]

[165]
Okafor, C.N.; Plankey, M.W.; Goodman-Meza, D.; Li, M.; Bautista, K.J.; Bolivar, H.; Phyllis, T.C.; Brown, T.T.; Shoptaw, S.J. Association between self-reported marijuana use and incident diabetes in women and men with and at risk for HIV. Drug Alcohol Depend.,  2020, 209, 107935.
 [http://dx.doi.org/10.1016/j.drugalcdep.2020.107935] [PMID: 32109711]

[166]
O’Connor, S.M.; Lietzan, E. The surprising reach of FDA regulation of Cannabis, even after descheduling. Am. Univ. Law Rev.,  2019, 68(3), 823-925.
 [PMID: 30919712]

[167]
Russo, E.; Guy, G.W. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses,  2006, 66(2), 234-246.
 [http://dx.doi.org/10.1016/j.mehy.2005.08.026] [PMID: 16209908]

[168]
Van Gaal, L.F.; Rissanen, A.M.; Scheen, A.J.; Ziegler, O.; Rössner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet,  2005, 365(9468), 1389-1397.
 [http://dx.doi.org/10.1016/S0140-6736(05)66374-X] [PMID: 15836887]

[169]
Specchio, N.; Pietrafusa, N.; Cross, H.J. Source of cannabinoids: What is available, what is used, and where does it come from? Epileptic Disord.,  2020, 22(S1), 1-9.

[170]
Abuhasira, R.; Shbiro, L.; Landschaft, Y. Medical use of Cannabis and cannabinoids containing products – Regulations in Europe and North America. Eur. J. Intern. Med.,  2018, 49, 2-6.
 [http://dx.doi.org/10.1016/j.ejim.2018.01.001] [PMID: 29329891]

[171]
Freeman, T.P.; Hindocha, C.; Green, S.F.; Bloomfield, M.A.P. Medicinal use of Cannabis based products and cannabinoids. BMJ,  2019, 365, l1141.
 [http://dx.doi.org/10.1136/bmj.l1141] [PMID: 30948383]

[172]
MacCallum, C.A.; Russo, E.B. Practical considerations in medical Cannabis administration and dosing. Eur. J. Intern. Med.,  2018, 49, 12-19.
 [http://dx.doi.org/10.1016/j.ejim.2018.01.004] [PMID: 29307505]

[173]
Goldenberg, M.; Reid, M.W.; IsHak, W.W.; Danovitch, I. The impact of Cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug Alcohol Depend.,  2017, 174, 80-90.
 [http://dx.doi.org/10.1016/j.drugalcdep.2016.12.030] [PMID: 28319753]
Cite As
Current Pharmaceutical Biotechnology

Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects

Abstract

Graphical Abstract
